ReviewOncogene2021
Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand.
Parasvi S Patel et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
52 papers cite it
this paperpooled ittrialcites it
ReviewOncogene2021
Parasvi S Patel et al.PubMed ↗Publisher ↗
No numbers read from the abstract.